TREE NEWS update: Eli Lilly is laying the groundwork for a broader push into women’s health, assembling expert teams and hunting for new drugs in areas including bone health and endometriosis. The company has recruited scientists to work on osteoporosis and preeclampsia, and hired reproductive medicine specialist Kelle Moley to lead women’s health and early clinical development. Lilly is also looking outside its own labs, making strategic investments in companies such as Absci Corp., which is developing an experimental endometriosis therapy.
Eli Lilly Builds Women’s Health Push, Invests in Absci
AI take
Lilly's move matters less as a single deal than as a signal that a large pharma is treating women's health as a pipeline category rather than a niche, with bone and reproductive conditions that have long lacked commercial attention. The Absci investment shows the strategy leans on external biotech for early-stage assets while Lilly supplies clinical and development scale. Whether that pattern extends to more partnerships, and whether endometriosis and preeclampsia programs advance beyond early work, is the open question worth tracking.
Generated by AI for reference only.
Share on WeChat
Open WeChat → Scan → then tap "…" to send to a chat or Moments.
Tap "…" in the top-right corner to send to a chat or share to Moments.
Related News
8m ago
Houthis Deploy Forces on Red Sea’s Hanish Islands After Yemeni Navy Withdraws
9m ago
Mexico’s Sheinbaum tells US: Don’t use Mexico in midterm elections
10m ago
Goldman Sachs Tests Demand for Meta-Linked Data Center Bonds
13m ago
Brent Tops $106, Rate-Hike Odds Hit 64% as Crypto Sells Off
26m ago
MSCI Emerging Market FX Index Posts Biggest One-Day Drop Since July
35m ago
Fatah Official Doubts Palestinian Legislative Election Will Be Held in November